Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 9,524Xls
2D Structure
Also known as: 14976-57-9, Tavist, Agasten, Clemastine hydrogen fumarate, Meclastine fumarate, Tavegil
Molecular Formula
C25H30ClNO5
Molecular Weight
460.0  g/mol
InChI Key
PMGQWSIVQFOFOQ-YKVZVUFRSA-N
FDA UNII
19259EGQ3D

A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-but-2-enedioic acid;(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
2.1.2 InChI
InChI=1S/C21H26ClNO.C4H4O4/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2;5-3(6)1-2-4(7)8/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t20-,21-;/m1./s1
2.1.3 InChI Key
PMGQWSIVQFOFOQ-YKVZVUFRSA-N
2.1.4 Canonical SMILES
CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
19259EGQ3D
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine

2. Clemastine

3. Hs 592

4. Hs-592

5. Hs592

6. Meclastine

7. Mecloprodin

8. Tavegyl

9. Tavist

2.3.2 Depositor-Supplied Synonyms

1. 14976-57-9

2. Tavist

3. Agasten

4. Clemastine Hydrogen Fumarate

5. Meclastine Fumarate

6. Tavegil

7. Clemastine (fumarate)

8. (r)-2-(2-((r)-1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine Fumarate

9. Chebi:3739

10. Mecloprodine

11. Aloginan

12. Xolamin

13. 19259egq3d

14. (+)-(2r)-2-(2-(((r)-p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine Fumarate (1:1)

15. 14976-57-9 (fumarate)

16. Alphamin

17. Anhistan

18. Clemanil

19. Fuluminol

20. Inbestan

21. Kinotomin

22. Lacretin

23. Lecasol

24. Maikohis

25. Marsthine

26. Masletine

27. Piloral

28. Reconin

29. Tavegyl

30. Trabest

31. Mallermin-f

32. Telgin-g

33. Dsstox_cid_27765

34. Dsstox_rid_82542

35. Dsstox_gsid_47785

36. Tavist-1

37. Pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (r-(r*,r*))-, (e)-2-butenedioate (1:1)

38. Meclastine Hydrogen Fumarate

39. (2e)-but-2-enedioic Acid; (2r)-2-{2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine

40. (e)-but-2-enedioic Acid;(2r)-2-[2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine

41. Hsdb 6507

42. Topcare Dayhist Allergy

43. Ncgc00016710-01

44. Contac 12 Hour Allergy

45. Einecs 239-055-2

46. Cas-14976-57-9

47. Clemastine For System Suitability

48. Unii-19259egq3d

49. (r)-2-[2-[(r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Fumarate

50. Prestwick_680

51. Meclastine (fumarate)

52. Clemastinefumarate,(s)

53. Clemastine Fumarate [usan:usp:ban:jan]

54. Hs-592 (fumarate)

55. (+)-2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl Pyrrolidine Fumarate

56. Schembl33403

57. Schembl41468

58. Spectrum1500191

59. Chembl1200795

60. Dtxsid6047785

61. Hms500o07

62. Hy-b0298a

63. Clemastine Fumarate [jan]

64. Clemastine Fumarate [hsdb]

65. Clemastine Fumarate [usan]

66. Hms1568n14

67. Hms1920o13

68. Hms2091e20

69. Hms2095n14

70. Hms3267l12

71. Hms3412b19

72. Hms3676b19

73. Hms3712n14

74. Hms3884k12

75. Pharmakon1600-01500191

76. Clemastine Fumarate [vandf]

77. Bcp27945

78. Clemastine Fumarate [mart.]

79. Tox21_110574

80. Ccg-40028

81. Clemastine Fumarate [usp-rs]

82. Clemastine Fumarate [who-dd]

83. Mfcd00137486

84. Nsc756685

85. S1847

86. Akos015896237

87. Akos037643271

88. Tox21_110574_1

89. Ac-1338

90. Clemastine Fumarate [orange Book]

91. Clemastine Hydrogen Fumarate [mi]

92. Ncgc00016710-05

93. Ncgc00180903-01

94. Ncgc00180903-02

95. (r-(r*,r*))-2-(2-(1-(p-chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidinium Hydrogen Fumarate

96. As-12093

97. Bc164321

98. Clemastine Fumarate [ep Monograph]

99. Pyrrolidine, 2-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methyl-, (+)-, Fumarate (1:1)

100. Clemastine Fumarate [usp Monograph]

101. Clemastine Fumarate Salt, >=98% (hplc)

102. Sw196835-3

103. Tavist-d Component Clemastine Fumarate

104. H10994

105. Clemastine Fumarate Component Of Tavist-d

106. 976c579

107. Sr-05000001590

108. Sr-05000001590-1

109. Q27106180

110. Clemastine Fumarate, European Pharmacopoeia (ep) Reference Standard

111. Clemastine Fumarate, United States Pharmacopeia (usp) Reference Standard

112. (2r)-2-[2-[(1r)-1-(4-chlorophenylethoxy]ethyl]-1-methyl-2-pyrrolidine Fumarate

113. Clemastine For System Suitability, European Pharmacopoeia (ep) Reference Standard

114. (+)-(2r)-2-(2-(((r)-p-chloro-.alpha.-methyl-.alpha.-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine Fumarate (1:1)

115. (2r)-2-[2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium;(e)-4-hydroxy-4-oxobut-2-enoate

116. (2r)-2-{2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine (2e)-but-2-enedioate

117. (2r)-2-{2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidinium (2e)-3-carboxyprop-2-enoate

118. Pyrrolidine,2-[2-[(1r)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2r)-,(2e)-2-butenedioate (1:1)

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 460.0 g/mol
Molecular Formula C25H30ClNO5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count8
Exact Mass459.1812508 g/mol
Monoisotopic Mass459.1812508 g/mol
Topological Polar Surface Area87.1 Ų
Heavy Atom Count32
Formal Charge0
Complexity495
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameClemastine fumarate
Active IngredientClemastine fumarate
Dosage FormTablet; Syrup
RouteOral
Strength1.34mg; 2.68mg; eq 0.5mg base/5ml
Market StatusOver the Counter; Prescription
CompanyWockhardt; Teva; Perrigo; Sandoz

2 of 4  
Drug NameTavist-1
Drug LabelClemastine belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-(2R)-2-[2-[[(R)-p-Chloro--methyl--phenylbenzyl]-oxy]ethyl]-1-methylpyrrolidine fumarate (1:1).C21H26C1NO.C4H4O4 M.W. 459.97Each tablet for oral...
Active IngredientClemastine fumarate
Dosage FormTablet
RouteOral
Strength1.34mg
Market StatusOver the Counter
CompanyNovartis

3 of 4  
Drug NameClemastine fumarate
Active IngredientClemastine fumarate
Dosage FormTablet; Syrup
RouteOral
Strength1.34mg; 2.68mg; eq 0.5mg base/5ml
Market StatusOver the Counter; Prescription
CompanyWockhardt; Teva; Perrigo; Sandoz

4 of 4  
Drug NameTavist-1
Drug LabelClemastine belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-(2R)-2-[2-[[(R)-p-Chloro--methyl--phenylbenzyl]-oxy]ethyl]-1-methylpyrrolidine fumarate (1:1).C21H26C1NO.C4H4O4 M.W. 459.97Each tablet for oral...
Active IngredientClemastine fumarate
Dosage FormTablet
RouteOral
Strength1.34mg
Market StatusOver the Counter
CompanyNovartis

4.2 Therapeutic Uses

For the symptomatic treatment of allergic rhinitis in adults and children 12 years of age and older ...

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 15


For the symptomatic treatment of mild allergic urticaria and angioedema in adults and children 12 years of age and older ...

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 15


This multicenter, double blind, randomized parallel group study compared 3 wk treatment with either loratadine (Clarityn) 10 mg once daily, or clemastine (Tavegyl) 1 mg twice daily, and placebo in outpatients with active perennial allergic rhinitis. 155 patients were evaluated for efficacy and safety. Grading of four nasal and three non-nasal symptoms, rhinoscopy signs, and therapeutic response was performed on treatment days 6, 13, and 20. Patients recorded daily symptoms and possible adverse experiences in a diary, also indicating when symptoms of active rhinitis were relieved. Loratadine and clemastine were statistically significantly superior to placebo throughout the study (p < 0.05), based on assessment of patients' nasal and eye symptoms, patients' diary scores, rhinoscopy signs of symptoms, and onset of relief. The loratadine group showed a statistically significantly (p < 0.05) faster onset of relief of symptoms compared with the group treated with clemastine. Concerning nasal stuffiness, loratadine was significantly (p < 0.05) superior to clemastine after 1 week's treatment. Reports of adverse reactions showed that significantly (p < 0.05) more patients complained of sedation in the clemastine than in the loratadine group. Regarding other adverse experiences and laboratory tests, the three treatment groups were statistically comparable (p < 0.05). The study showed that compared with placebo both loratadine and clemastine were effective in relieving nasal and eye symptoms in patients with perennial allergic rhinitis. Loratadine was safe and well tolerated and was significantly less sedative than clemastine; loratadine may therefore possess an advantage in clinical use in the treatment of perennial allergic rhinitis.

PMID:2143361 Frolund L et al; Allergy 45 (4): 254-61 (1990)


The effects of cromolyn sodium (sodium cromoglycate), clemastine and ketotifen administered to the nasal mucosa of seasonal and perennial allergic rhinitis patients 30 min before provocation with histamine and allergen were compared in a randomized, double blind, placebo controlled study. Clemastine and cromolyn sodium, but not ketotifen, significantly inhibited the nasal response to increasing concentrations of histamine. None of the drugs administered in the concentrations used significantly inhibited the nasal response to allergen.

PMID:3117084 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386248 Corrado OJ et al; Br J Clin Pharmacol 24 (Sep): 283-92 (1987)


4.3 Drug Warning

Drugs contraindicated during lactation include ... clemastine.

Ellenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 113


There are no adequate and controlled studies to date using clemastine fumarate alone or in fixed combination with phenylpropanolamine in pregnant women, and the drug should be used during pregnancy only when clearly needed.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 15


Because of the potential for serious adverse reactions to clemastine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 15


Drugs that have been associated with Significant Effects on some Nursing Infants and should be given to Nursing Mothers with Caution: Clemastine: Drowsiness, irritability, refusal to feed, high-pitched cry, neck stiffness (1 case). /from Table 5/

Report of the American Academy of Pediatrics Committee on Drugs in Pediatrics 93 (1): 139 (1994)


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antipruritics

Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)


Anti-Allergic Agents

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)


Histamine H1 Antagonists

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)


5.2 Absorption, Distribution and Excretion

In 12 healthy subjects given clemastine fumarate by mouth peak plasma concentrations occurred after 3 to 5 hr. After intravenous injection in 3 subjects a rapid decline in plasma concentration during the first 30 minutes occurred followed by a slow rise to peak concentration 2 to 3 hours after administraton. In 5 subjects given clemastine fumarate the ability to inhibit histamine flares correlated well with plasma concentation.

Reynolds, J.E.F., Prasad, A.B. (eds.) Martindale-The Extra Pharmacopoeia. 28th ed. London: The Pharmaceutical Press, 1982., p. 1307


Clemastine fumarate is rapidly and almost completely absorbed from the GI tract. Peak plasma concentrations of the drug are attained within 2-5 hours after a single oral dose. Following oral administration of clemastine fumarate, the antihistaminic effect of the drug (as measured by suppression of the wheal response induced by intradermal injection of histamine) is maximal within 5-7 hours and persists for 10-12 and, in some individuals, up to 24 hours.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 14


Distribution of clemastine into human body fluids and tissues has not been fully characterized, but the drug has been shown to distribute into milk. Following oral administration of 2.68 mg of clemastine fumarate daily for 3 days in one nursing woman, a milk clemastine concentration of about 5-10 ug/ml occurred 20 hours after the last dose of the drug and was about 25-50% of the stimultaneous maternal plasma drug concentration; clemastine was undetectable in milk 6 days after discontuance of the drug.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 14


Clemastine and its metabolites are eliminated principally in urine.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 14


5.3 Metabolism/Metabolites

The exact metabolic fate of clemastine is not clearly established, but the drug appears to be extensively metabolized. Clemastine and its metabolites are eliminated principally in urine.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 14


Time to peak concentration: 2-4 hr

US Pharmacopeial Convention; US Pharmacopeia Dispensing Information (USP DI); Drug Information for the Health Care Professional 12th ed, V.I p.403 (1992)


5.4 Mechanism of Action

Inhibitory effects of various histamine receptor-blocking agents including antiallergic agents on metabolic activations of neutrophils were examined by measuring leukotrienes (C4, D4 and E4) formation, arachidonic acid release and superoxide generation. The stimulation of neutrophils by calcium ionophore causes the production of leukotrienes concomitantly with the release of arachidonic acid from the cells and these were effectively diminished with a variety of antihistaminic agents. Almost all the histamine H1 receptor-blocking drugs studied here showed as inhibitors of the metabolic activations of neutrophils, although the degree was dependent on the drug concentrations. The order of potency of the inhibitory effects on the arachidonic acid release were: homochlorcyclizine, clemastine, and azelastine (IC50 < 20 microM) greater than oxatomide (IC50 < 60 microM) and diphenylpyraline greater than triprolidine, meclizine, diphenhydramine (IC50 > 100 microM). The superoxide generation from neutrophils activated by phorbol 12-myristate 13-acetate was also effectively inhibited by these agents, but generally lower concentrations were required to obtain the same degrees of effects. These results indicated that some of the histamine H1 receptor-blocking drugs, such as clemastine and homochlorcyclizine, may act as inhibitors of formation of leukotrienes at the locus of inflammation.

PMID:1678430 Taniguchi K et al; J Pharmacobiodyn 14 (2): 87-93 (1991)